Understanding the molecular drivers of Parkinson’s disease is essential for developing effective treatments and the LRRK2 gene remains one of the most significant contributors to both inherited and sporadic forms of the condition.
To investigate this, researchers led by Dr Sally Cowley at the Oxford Parkinson’s Disease Centre have shared a set of LRRK2 gene-edited iPSC lines, including isogenic knockouts and disease-associated variants. These models were generated from high-quality parental lines originally developed through the StemBANCC collaboration, demonstrating the continued impact of large, multi-partner initiatives in building resources which can be shared and used by all researchers.
These iPSC lines are fully quality-controlled and come with comprehensive metadata, enabling robust and reproducible studies of LRRK2 function, cellular pathology, and therapeutic targets.
🔬 Explore these LRRK2 iPSC lines in the EBiSC catalogue: https://ebisc.org/search?q=&hpscreg-genes=%5B%22LRRK2%22%5D&product-status=%5B%5D&gene-edited=true